1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
BrightGene Bio-Medical Technology Co. Ltd. Class A

BrightGene Bio-Medical Technology Co. Ltd. Class A

SSSE:688166
30.70
CNY
-1.35
(-4.21%)
0.18EPS
226.79P/E
15.26BMarket Cap
Oct 30Next Earn
BrightGene Bio-Medical Technology Co. Ltd. Class A
SSE:688166
(Shanghai Stock Exchange)

Recent

price

30.70

P/E

ratio

226.79

div

yld

1.00%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.71
0.97
1.17
1.36
1.9
2.59
2.46
2.8
3.05
2.92
3.02
Revenue per Share
0.06
0.14
0.21
0.3
0.41
0.6
0.58
0.48
0.45
0.13
0.15
Basic EPS, GAAP
-0.02
-0.15
-0.14
-0.08
-0.48
-1.8
-1.01
-0.5
-0.03
-0.31
- -
Free Cash Flow per Basic Share
0.01
0.01
- -
- -
0.09
0.13
0.24
0.27
0.32
0.28
0.31
Dividend per Share
5.47
9.99
15.87
3.2
3.49
4.09
5.19
5.61
5.64
5.96
7
Book Value per Share
5.27
9.81
14.83
3.08
3.37
3.88
4.98
5.37
5.39
5.06
5.95
Tangible Book Value per Share
284
328
349
370
414
407
413
422
420
419
436
Basic Weighted Avg Shares
201
317
408
503
785
1,052
1,017
1,180
1,283
1,224
1,316
Sales/Revenue/Turnover
9.3
17.85
21.3
24.97
25.79
26.07
26.01
21.5
19.56
9.01
13.5
Operating Margin (%)
14
15
18
26
30
41
50
78
111
159
- -
Depreciation Expense
17
46
73
111
170
244
240
202
189
55
67
Net Income, GAAP
11.98
5.89
7.6
7.39
11.48
7.73
12.71
8.13
10.14
- -
- -
Effective Tax Rate (%)
8.49
14.48
17.96
22.08
21.63
23.18
23.55
17.17
14.75
4.46
5.12
Profit Margin (%)
45
221
457
954
655
410
1,127
917
588
508
1,224
Working Capital
- -
- -
- -
- -
78
619
1,582
1,636
1,575
1,399
1,834
LT Debt
220
446
767
1,313
1,433
1,742
2,242
2,418
2,426
2,846
3,430
Total Equity
- -
12.59
12.59
10.95
11.62
11.18
6.13
3.94
3.11
- -
- -
Return on Invested Capital (%)
- -
12.91
12.13
10.7
11.61
12.07
8.35
6.13
6.13
- -
- -
Return on Capital (%)
- -
13.77
12.06
10.68
12.38
15.69
12.38
8.88
7.96
2.22
2.42
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
955
728
760
LT Borrowings
1,388
2,335
1,812
LT Finance Leases
10
26
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
423
423
436
Market Capitalization
20,757
20,508
15,257

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,789
2,307
2,202
Cash, Cash Equivalents & STI
961
1,395
1,342
Accounts Receivable, Net
316
385
399
Inventories
364
359
333
Total Current Liabilities
1,280
991
978
Payables & Accruals
- -
- -
- -
ST Debt
955
728
760
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.16%
17.32%
Free Cash Flow
- -
216.23%
1,001.54%
Net Income, GAAP
- -
-10.29%
-71.18%
Sales/Revenue/Turnover
- -
10.15%
-4.59%
Total Cash Common Dividend
- -
31.46%
-13.36%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
340
318
319
306
1,283
2025
249
288
- -
349
1,224
2026
325
353
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.1
0.17
0.03
0.45
2025
0.03
0.01
- -
0.01
0.13
2026
0.02
0.11
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.03
0.18
0.04
0.32
2025
0.05
0.14
- -
0.06
0.28
2026
0.03
0.08
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
BrightGene Bio-Medical Technology Co., Ltd. is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of complex active pharmaceutical ingredients (APIs), key pharmaceutical intermediates, finished dosage formulations, and innovative chemical and biological therapeutics. Founded in 2001 and headquartered in Suzhou, China, the company operates across the global pharmaceutical and healthcare sectors, supplying generic drug manufacturers, biotechnology companies, and healthcare providers across domestic and international markets, including the United States, the European Union, Japan, and South Korea. The company organizes its business operations into specialized pharmaceutical development, API manufacturing, finished formulation production, and contract development and manufacturing organization (CDMO) services. Its primary product and service offerings comprise high-barrier active pharmaceutical ingredients and finished dosage forms across several major therapeutic categories: antifungal agents, including caspofungin acetate, micafungin sodium, and anidulafungin; antineoplastic and oncology drugs, including eribulin mesylate, cabazitaxel, bortezomib, and regorafenib; antiviral therapies, including oseltamivir phosphate, entecavir, and tenofovir derivatives; cardiovascular and anticoagulant agents, including fondaparinux sodium and apixaban; immunosuppressant and dermatological treatments, including pimecrolimus and voclosporin; complex injectable formulations and inhalation suspensions; and integrated CDMO, technology licensing, process development, and regulatory support services delivered through subsidiaries such as BrightGene (Taixing) Pharmaceutical Co., Ltd., Changshu Boyuan Pharmaceutical Co., Ltd., and BrightGene (Hainan) Pharmaceutical Co., Ltd. In recent strategic developments, BrightGene Bio-Medical Technology Co., Ltd. has expanded its focus from complex generic APIs toward proprietary innovative biopharmaceuticals, highlighted by the clinical advancement of BGM0504, an investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist undergoing mid-to-late-stage clinical trials for the treatment of type 2 diabetes mellitus and chronic weight management. The company has also expanded its clinical pipeline in respiratory inhalation therapies and targeted drug delivery conjugates, scaled its high-potency active pharmaceutical ingredient (HPAPI) and peptide manufacturing infrastructure, and strengthened international distribution partnerships and regulatory filings with global authorities, including the United States Food and Drug Administration and European regulatory agencies, to support global commercialization of its formulation portfolio.